Bioequivalence Study of Selexipag 400 mcg Tablets in Fed Condition

Phase 1, randomised, open-label trial of selexipag in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Humanis. Primary endpoints: Maximum observed plasma concentration at 20 hours and Area under the plasma concentration-time curve from time zero to last measurable concentration at 20 hours. Started Apr 2026; status: completed.